New trial
Phase 2 trial: BMS-986340, a CCR8-targeting antibody, in advanced microsatellite-stable colorectal cancer
- Trial ID
- NCT07011550 on ClinicalTrials.gov
- Cancer type
- Colorectal Cancer
- Stage of research
- Exploratory
- Published in
- New in Oncology - July 3, 2025
The study evaluates a single‐arm regimen combining BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab for patients with advanced or metastatic refractory microsatellite-stable colorectal cancer. Conducted by M.D. Anderson Cancer Center, it explores a novel CCR8-directed approach in a challenging treatment setting.
More in colorectal cancer
-
New trial · Oct 15, 2026 · NCT07750158
Phase 3 STELLAR-316 tests zanzalintinib with or without pembrolizumab for ctDNA-positive, scan-negative colorectal cancer -
New trial · Oct 15, 2026 · NCT07842965
Phase 1/1b CHAMP adds CCR5 blockade with leronlimab to surgery, hepatic arterial floxuridine, and systemic therapy for colorectal liver metastases -
New trial · Oct 15, 2026 · NCT07551596
Phase 2 COMBAT tests botensilimab plus balstilimab for ctDNA-positive molecular residual disease in MSS colorectal cancer -
New trial · Oct 8, 2026 · NCT07811193
Phase 2 VVD-133214 WRN helicase covalent inhibitor + pembrolizumab (PD-1 antibody) in MSI/dMMR CRC -
New trial · Oct 8, 2026 · NCT07808151
Phase 2 porustobart CTLA-4 antibody + pembrolizumab PD-1 antibody in resectable MSS colon cancer